UBS Group AG - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 76 filers reported holding LYELL IMMUNOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.6%.

Quarter-by-quarter ownership
UBS Group AG ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$286,761
-41.1%
195,076
+27.4%
0.00%
Q2 2023$487,106
-6.7%
153,178
-30.8%
0.00%
Q1 2023$522,228
-63.4%
221,283
-46.2%
0.00%
-100.0%
Q4 2022$1,426,260
+857.2%
411,026
+1923.0%
0.00%
Q3 2022$149,000
+338.2%
20,318
+289.4%
0.00%
Q2 2022$34,000
+36.0%
5,218
+4.4%
0.00%
Q1 2022$25,000
-77.7%
5,000
-65.3%
0.00%
Q4 2021$112,000
+2700.0%
14,408
+5276.1%
0.00%
Q3 2021$4,0002680.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders